An oriP expression vector containing the HIV-1 Tat/TAR transactivation axis produces high levels of protein expression in mammalian cells

被引:9
作者
Cho, MS [1 ]
Yee, H
Brown, C
Jeang, KT
Chan, S
机构
[1] Bayer Corp, Mol & Cell Biol Proc Sci Biotechnol, Berkeley, CA USA
[2] NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA
关键词
HKB11; cells; IL-2; mutein; mammalian cell expression; oriP; Tat/TAR;
D O I
10.1023/A:1016124911071
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A mammalian gene expression vector based on cytomegalovirus (CMV) enhancer/promoter (CMVe/p) for the regulation of gene expression was further optimized by adding oriP elements derived from Epstein-Barr virus (EBV) and the Tat/TAR transactivation axis from human immunodeficiency virus type 1 (HIV-1). Using the Tat/TAR-oriP expression vector, a transient transfection system was optimized for an extended culture period to produce large amounts of secreted IL-2SA (an IL-2 mutein) in HKB11 cells. We observed a 4-fold increase in IL-2SA expression in cells transfected with vectors containing the HIV-1 transactivation axis (Tat/TAR) or oriP elements alone when compared to cells transfected with the control vector having a CMVe/p. Cells transfected with expression vectors equipped with both oriP and Tat/TAR showed an 18-fold increase in IL-2SA expression. This transient transfection system maintained high secretion of IL-2SA for a period of 10-day with no appreciable loss in expression. We demonstrate that during this 10-day culture period, it was possible to produce 1-100 mg of proteins using 500 mug of plasmid DNA.
引用
收藏
页码:23 / 30
页数:8
相关论文
共 17 条
[1]   TAT TRANS-ACTIVATES THE HUMAN IMMUNODEFICIENCY VIRUS THROUGH A NASCENT RNA TARGET [J].
BERKHOUT, B ;
SILVERMAN, RH ;
JEANG, KT .
CELL, 1989, 59 (02) :273-282
[2]  
CACHIANES G, 1993, BIOTECHNIQUES, V15, P255
[3]   HUMAN CYTOMEGALOVIRUS-IE1 TRANSACTIVATES THE ALPHA-PROMOTER-ENHANCER VIA AN 18-BASE-PAIR REPEAT ELEMENT [J].
CHERRINGTON, JM ;
MOCARSKI, ES .
JOURNAL OF VIROLOGY, 1989, 63 (03) :1435-1440
[4]  
Cho M.S., 2000, U.S. Patent, Patent No. 6136599
[5]   TRANSACTIVATION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS LONG TERMINAL REPEAT SEQUENCE BY DNA VIRUSES [J].
GENDELMAN, HE ;
PHELPS, W ;
FEIGENBAUM, L ;
OSTROVE, JM ;
ADACHI, A ;
HOWLEY, PM ;
KHOURY, G ;
GINSBERG, HS ;
MARTIN, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (24) :9759-9763
[6]   THE E4 TRANSCRIPTIONAL UNIT OF AD2 - FAR UPSTREAM SEQUENCES ARE REQUIRED FOR ITS TRANSACTIVATION BY E1A [J].
GILARDI, P ;
PERRICAUDET, M .
NUCLEIC ACIDS RESEARCH, 1984, 12 (20) :7877-7888
[7]  
HASELTINE WA, 1998, Patent No. 5801056
[8]   THE EPSTEIN-BARR VIRUS IMMEDIATE-EARLY GENE-PRODUCT, BMLF1, ACTS IN TRANS BY A POSTTRANSCRIPTIONAL MECHANISM WHICH IS REPORTER GENE DEPENDENT [J].
KENNEY, S ;
KAMINE, J ;
HOLLEYGUTHRIE, E ;
MAR, EC ;
LIN, JC ;
MARKOVITZ, D ;
PAGANO, J .
JOURNAL OF VIROLOGY, 1989, 63 (09) :3870-3877
[9]   PROMISCUOUS TRANS ACTIVATION OF GENE-EXPRESSION BY AN EPSTEIN-BARR VIRUS-ENCODED EARLY NUCLEAR-PROTEIN [J].
LIEBERMAN, PM ;
OHARE, P ;
HAYWARD, GS ;
HAYWARD, SD .
JOURNAL OF VIROLOGY, 1986, 60 (01) :140-148
[10]  
MCARTHUR JG, 1991, J BIOL CHEM, V266, P6000